Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
Autor: | Giorgia Bodini, Lorenzo Bertani, Davide Massimi, Renata D'Incà, Fabiana Zingone, A. Gubbiotti, Brigida Barberio, Matteo Ghisa, Edoardo Savarino, Greta Lorenzon, Laura Rovigo |
---|---|
Rok vydání: | 2020 |
Předmět: |
Adult
Male medicine.medical_specialty Adolescent Colon Gastroenterology Inflammatory bowel disease Severity of Illness Index Article 03 medical and health sciences Young Adult 0302 clinical medicine Crohn Disease Gastrointestinal Agents Ileum Internal medicine medicine Adalimumab Humans Intestinal Mucosa Adverse effect Biosimilar Pharmaceuticals Aged Retrospective Studies Aged 80 and over Crohn's disease Biological Products business.industry Tumor Necrosis Factor-alpha Inflammatory Bowel Disease Remission Induction Retrospective cohort study Colonoscopy Middle Aged medicine.disease Ulcerative colitis Infliximab Treatment Outcome Tolerability 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Colitis Ulcerative Female business medicine.drug |
Zdroj: | Clinical and Translational Gastroenterology |
ISSN: | 2155-384X |
Popis: | INTRODUCTION: There are no real-life studies comparing the efficacy and safety of the different antitumor necrosis factor (TNF)-α drugs available in patients with ulcerative colitis (UC) and Crohn's disease (CD). To verify the effectiveness and tolerability of different anti–TNF-α agents (infliximab [IFX] originator, biosimilar CTP13, and adalimumab [ADA]) in patients with moderate-to-severe CD and UC. METHODS: Retrospectively, patients with moderate-to-severe inflammatory bowel disease who completed induction with either ADA, IFX originator, or biosimilar from 2015 to 2017 were included. Patients were evaluated after induction at 30 and 52 weeks. We performed an intention-to-treat analysis to evaluate clinical response and remission, steroid-free clinical remission, and endoscopy response according to different time points. At every time point, the need for dose escalation and occurrence of adverse events have been reported. RESULTS: Eighty-nine patients with UC (31 ADA, 30 IFX originator, and 28 IFX biosimilar) and 90 patients with CD (30 for each drug groups) were enrolled. After induction at week 30 and 52, clinical response was obtained by the following: 84.3%, 86.5%, and 82% of UC and 93.3%, 88.9%, and 80% of CD. Clinical steroid-free remission rates were significantly higher in the CD group compared with the UC group at every time point (P < 0.05). At week 52, 31.1% of ADA, 16.7% of IFX originator, and 36.2% of biosimilar patients needed treatment optimization. At week 52, 13 patients had suspended therapy because of severe adverse events, including 3 cases of malignant disease. DISCUSSION: Anti–TNF-α treatment was more effective in patients with CD compared to patients with UC, independently of the drug used. |
Databáze: | OpenAIRE |
Externí odkaz: |